TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34370076

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID with rosuvastatin 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg BID with oral contraceptives
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral contraceptives (ethinylestradiol 30 µg + levonorgestrel 150 µg)
Number of subjects: 36
Study: 34370116

Group type: EXPERIMENTAL
Intervention: P/FP ratio with PEEP levels > 5 cmH2O
Number of subjects: 3442

Group type: COMPARATOR
Intervention: P/F ratio
Number of subjects: 3442
Study: 34370760

Group type: EXPERIMENTAL
Intervention: 3D CAD/CAM designed Boston 3D-brace
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard Boston brace
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups (3D CAD/CAM and Standard Boston brace)
Number of subjects: 170
Study: 34370839

Group type: EXPERIMENTAL
Intervention: Anticancer drugs (40 drugs significantly associated with diLQT)
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Anticancer drugs (9 drugs associated with VA without diLQT)
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Kinase inhibitors (20/49 drugs)
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Hormonal therapies (4/49 drugs)
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Immunotherapies (3/49 drugs)
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Cytotoxics (12/49 drugs)
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Miscellaneous (10/49 drugs)
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Anticancer drugs reporting
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: VigiBase signals
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: New signals from drugs
Number of subjects: 18441659

Group type: EXPERIMENTAL
Intervention: Risk stratification
Number of subjects: 18441659
Study: 34371257

Group type: EXPERIMENTAL
Intervention: Preoperative pain catastrophizing scale (N-PCS) scores
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Preoperative pain catastrophizing
Number of subjects: 131
Study: 34371294

Group type: EXPERIMENTAL
Intervention: Hypoglossal nerve stimulator implantation
Number of subjects: 4
Study: 34371366

Group type: EXPERIMENTAL
Intervention: quavonlimab 75 mg Q6W plus pembrolizumab 200 mg Q3W
Number of subjects: 40
Study: 34371380

Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 1

Group type: COMPARATOR
Intervention: Alectinib
Number of subjects: 1
Study: 34372839

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 230
Study: 34372888

Group type: EXPERIMENTAL
Intervention: Functional alignment (FA) TKA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mechanical alignment (MA) TKA
Number of subjects: 100
Study: 34372905

Group type: EXPERIMENTAL
Intervention: FibriCheck® app on top of standard opportunistic screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard opportunistic screening only
Number of subjects: 0
Study: 34372979

Group type: EXPERIMENTAL
Intervention: Avelumab (from the JAVELIN Solid Tumor trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-schedule matching (ASM)
Number of subjects: 0
Study: 34373138

Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Risk score
Number of subjects: 1088
Study: 34373186

Group type: EXPERIMENTAL
Intervention: rabbit anti-thymocyte globulin (ATG) 3 mg/kg on day 8 post-transplant
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no ATG treatment)
Number of subjects: 68
Study: 34373315

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose tissue-derived mesenchymal stem cells (AD-MSCs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Allogeneic AD-MSCs
Number of subjects: 30
Study: 34373347

Group type: EXPERIMENTAL
Intervention: STOP-Bang questionnaire and resting daytime oxyhemoglobin saturation (SpO2)
Number of subjects: 199
Study: 34373952

Group type: EXPERIMENTAL
Intervention: Daily values or trends of clinical parameters associated with acute organ dysfunction, acid-base derangement, coagulation impairment, or systemic inflammation.
Number of subjects: 1260
Study: 34374151

Group type: EXPERIMENTAL
Intervention: Use of wagering inducements
Number of subjects: 14988
Study: 34374424

Group type: EXPERIMENTAL
Intervention: Echinocandins
Number of subjects: 541

Group type: COMPARATOR
Intervention: Triazoles or Amphotericin B
Number of subjects: 541
Study: 34374619

Group type: EXPERIMENTAL
Intervention: Low-income group (family income < US$350)
Number of subjects: 542

Group type: COMPARATOR
Intervention: High-income group (family income > US$350)
Number of subjects: 542
Study: 34374622

Group type: EXPERIMENTAL
Intervention: Asthma Control Test™ (ACT™) scores
Number of subjects: 1109

Group type: COMPARATOR
Intervention: Specialist assessment of asthma control
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Global Evaluation of Treatment Effectiveness (GETE)
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Biologics treatment
Number of subjects: 1109
Study: 34374848

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation on postoperative day 1 or 2 for symptomatic patients (68 patients treated for hypocalcemia)
Number of subjects: 477

Group type: COMPARATOR
Intervention: No supplementation for patients with calcemia ≥ 2.16 mmol/l and PTH ≥ 1.9 pmol/l
Number of subjects: 477

Group type: COMPARATOR
Intervention: No treatment for patients with calcemia between 1.9 and 2.16 mmol/l and PTH > 4.7 pmol/l
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Calcemia between 1.9 and 2.16 mmol/l and PTH > 1.9 pmol/l
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Combination of corrected calcemia and PTH on POD1
Number of subjects: 477
Study: 34374951

Group type: EXPERIMENTAL
Intervention: Bamlanivimab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bamlanivimab and Etesevimab together
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutralizing monoclonal antibodies (mAbs)
Number of subjects: 0
Study: 34374952

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 101

Group type: COMPARATOR
Intervention: Comparator (carbapenems)
Number of subjects: 101
Study: 34375311

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 9
Study: 34375314

Group type: EXPERIMENTAL
Intervention: Hhip-expressing lung fibroblasts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hhip+/- mice
Number of subjects: 0
Study: 34375315

Group type: EXPERIMENTAL
Intervention: bNAb-derived CAR T cell therapy
Number of subjects: 14
Study: 34375343

Group type: EXPERIMENTAL
Intervention: Universal testing and treatment approach (HIV testing and ART initiation)
Number of subjects: 13228
Study: 34375394

Group type: EXPERIMENTAL
Intervention: Balanced solution (n=5522)
Number of subjects: 11052

Group type: COMPARATOR
Intervention: 0.9% saline solution (n=5530)
Number of subjects: 11052

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 11052
Study: 34375411

Group type: EXPERIMENTAL
Intervention: Prognostic score for mortality at 3 months after discharge from AGU
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: Prognostic score for mortality at 12 months after discharge from AGU
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: Area under the curve for the prognostic score at 3 months
Number of subjects: 3112

Group type: EXPERIMENTAL
Intervention: Area under the curve for the prognostic score at 12 months
Number of subjects: 3112
Study: 34375748

Group type: EXPERIMENTAL
Intervention: Visit-based reminders in EHR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visit-based reminders with population health outreach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visit-based reminders, population health outreach, and patient navigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 34375986

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 50
Study: 34376064

Group type: EXPERIMENTAL
Intervention: ESC 0/1h-hs-cTnT-algorithm with hs-cTnT change <7 ng/L
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: ESC 0/1h-hs-cTnT-algorithm with hs-cTnT change ≥7 ng/L
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: Novel derived 0/3h-criteria for observe-zone patients with hs-cTnT concentration <15 ng/L and absolute change <4 ng/L
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: Novel derived 0/3h-criteria with absolute change ≥6 ng/L
Number of subjects: 2076

Group type: EXPERIMENTAL
Intervention: Novel 0/3h-criteria overall
Number of subjects: 2076
Study: 34376155

Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 25
Study: 34376480

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1000
Study: 34376534

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy (NADIM clinical trial, NCT03081689)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TCR repertoire analysis
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TCR most frequently ranked clones (top 1%)
Number of subjects: 40
Study: 34376552

Group type: EXPERIMENTAL
Intervention: TMEscore in patients treated with pembrolizumab, N=45
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: TMEscore validated in multicenter advanced gastric cancer cohort using NanoString technology, N=48
Number of subjects: 45
Study: 34376578

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors
Number of subjects: 0
Study: 34376579

Group type: EXPERIMENTAL
Intervention: Isatuximab (CD38 monoclonal antibody)
Number of subjects: 50
Study: 34376577

Group type: EXPERIMENTAL
Intervention: Itraconazole; specific dosage and duration not mentioned
Number of subjects: 0
Study: 34376809

Group type: EXPERIMENTAL
Intervention: PA coaching (n=30)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Usual care (n=25)
Number of subjects: 55
Study: 34377150

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 34377216

Group type: EXPERIMENTAL
Intervention: Dispositional mindfulness
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine daily stressors
Number of subjects: 114

Group type: COMPARATOR
Intervention: Acute or traumatic line-of-duty stressors
Number of subjects: 114

Group type: COMPARATOR
Intervention: Interpersonal stressors
Number of subjects: 114
Study: 34377592

Group type: EXPERIMENTAL
Intervention: Autologous EBV-expanded cytotoxic T lymphocytes (CTLs) in combination with gemcitabine and carboplatin chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCR repertoire characteristics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TCR Motif Analysis
Number of subjects: 0
Study: 34377890

Group type: EXPERIMENTAL
Intervention: CT-P13 (infliximab biosimilar)
Number of subjects: 334
Study: 34377989

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV) + Ofranergene Obadenovec (BV+VB-111)
Number of subjects: 170
Study: 34378249

Group type: EXPERIMENTAL
Intervention: Five-item FiberScreen
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 18-item FiberScreen
Number of subjects: 160
Study: 34378280

Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec
Number of subjects: 7
Study: 34378434

Group type: EXPERIMENTAL
Intervention: Standard Behavioral Parent Training
Number of subjects: 0
Study: 34378446

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg/day at baseline and month 12, with further as-needed 3-day courses.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous interferon beta-1a (SC IFNB-1a) 44 µg 3×/week.
Number of subjects: 0
Study: 34378539

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day
Number of subjects: 0
Study: 34379285

Group type: EXPERIMENTAL
Intervention: Crisaborole (1 on-treatment cycle)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Crisaborole (2 consecutive on-treatment cycles)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Crisaborole (3 consecutive on-treatment cycles)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Crisaborole (4 consecutive on-treatment cycles)
Number of subjects: 418
Study: 34379629

Group type: EXPERIMENTAL
Intervention: ER2 assessment (high-risk group)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: ER2 assessment (medium-risk group)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: ER2 assessment (low-risk group)
Number of subjects: 1800
Study: 34379916

Group type: EXPERIMENTAL
Intervention: CIS43LS (5 mg/kg, 20 mg/kg, 40 mg/kg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CIS43LS (40 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no CIS43LS)
Number of subjects: 25
Study: 34380334

Group type: EXPERIMENTAL
Intervention: Shockwave Peripheral IVL System
Number of subjects: 101
Study: 34380437

Group type: EXPERIMENTAL
Intervention: Emergency laparotomy (EL)
Number of subjects: 663
Study: 34380499

Group type: EXPERIMENTAL
Intervention: Maternal eating competence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal restrained and external eating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feeding to soothe at 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feeding to soothe at 6 months
Number of subjects: 0
Study: 34380527

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Generic nudge (text reminder)
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Optimized nudge
Number of subjects: 10000

Group type: EXPERIMENTAL
Intervention: Optimized nudge plus interactive AI chat bot
Number of subjects: 10000
Study: 34380536

Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) as induction therapy for 24 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) as maintenance therapy for 24 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cyclophosphamide as induction therapy for 24 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Azathioprine as maintenance therapy for 24 weeks
Number of subjects: 120
Study: 34380539

Group type: EXPERIMENTAL
Intervention: Cardiac arrest team interventions
Number of subjects: 68
Study: 34380543

Group type: EXPERIMENTAL
Intervention: Routine CSF sampling followed by a second sample after 10 min, with patient repositioning.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine CSF sampling followed by a second sample after 10 min, without patient repositioning.
Number of subjects: 51
Study: 34380567

Group type: EXPERIMENTAL
Intervention: At-birth point-of-care (POC) HIV testing
Number of subjects: 48
Study: 34380625

Group type: EXPERIMENTAL
Intervention: CCW702 (a bispecific antibody)
Number of subjects: 0
Study: 34380634

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34380662

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks until disease progression/unacceptable toxicity
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: t-DNA and cytopathology
Number of subjects: 13
Study: 34380663

Group type: EXPERIMENTAL
Intervention: Ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks)
Number of subjects: 16
Study: 34380722

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation in acute brain injured patients
Number of subjects: 0
Study: 34380724

Group type: EXPERIMENTAL
Intervention: Rapid molecular point-of-care (POC) assay for streptococcal pharyngitis
Number of subjects: 352

Group type: COMPARATOR
Intervention: Standard laboratory-based testing
Number of subjects: 352
Study: 34380725

Group type: EXPERIMENTAL
Intervention: Therapeutic fasting followed by a plant-based dietary intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional nutritional counselling focusing on an anti-inflammatory dietary pattern
Number of subjects: 84
Study: 34380979

Group type: EXPERIMENTAL
Intervention: 3HP treatment (rifapentine plus isoniazid) delivered by RN/CHW program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Historical clinic-based control
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 3HP treatment
Number of subjects: 50
Study: 34381030

Group type: EXPERIMENTAL
Intervention: Convalescent plasma from geographically proximate donors
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Convalescent plasma from non-proximate donors
Number of subjects: 28000
Study: 34381339

Group type: EXPERIMENTAL
Intervention: Chronic fatigue patients (n=19)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients without chronic fatigue (n=11)
Number of subjects: 30
Study: 34381382

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT), details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group details not available
Number of subjects: 0
Study: 34381802

Group type: EXPERIMENTAL
Intervention: Low-Speed Resistance Training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Speed Resistance Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 0
Study: 34381825

Group type: EXPERIMENTAL
Intervention: Therapeutic decision-making
Number of subjects: 0
Study: 34381870

Group type: EXPERIMENTAL
Intervention: LAAO using the Amplatzer™ Amulet™ device
Number of subjects: 1088
Study: 34382075

Group type: EXPERIMENTAL
Intervention: Endometrial progesterone (P4) levels and 17α-hydroxyprogesterone levels measured after 5 days of vaginal treatment with micronised progesterone (400 mg/12 h) and oestradiol valerate (6 mg/day).
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Endometrial receptivity assessed by the ERA® test.
Number of subjects: 79
Study: 34382135

Group type: EXPERIMENTAL
Intervention: Ultrasound EFW
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical EFW
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ultrasound EFW in macrosomic fetal group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical EFW in macrosomic fetal group
Number of subjects: 100
Study: 34382290

Group type: EXPERIMENTAL
Intervention: Low brain lesion load (<50 DWI-HL per patient)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High brain lesion load (≥100 DWI-HL)
Number of subjects: 23
Study: 34382365

Group type: EXPERIMENTAL
Intervention: pegargiminase (36 mg/m) plus pemetrexed and cisplatin (ADIPemCis)
Number of subjects: 21
Study: 34382603

Group type: COMPARATOR
Intervention: CS-Only
Number of subjects: 30

Group type: COMPARATOR
Intervention: CS&Attention
Number of subjects: 30

Group type: COMPARATOR
Intervention: CS&Positive
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CS&Negative
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CS pain
Number of subjects: 30
Study: 34382998

Group type: EXPERIMENTAL
Intervention: Cetuximab plus Avelumab
Number of subjects: 77
Study: 34383157

Group type: EXPERIMENTAL
Intervention: Gatherings with non-household members (NHM) during Thanksgiving
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Gatherings with non-household members (NHM) during winter holidays (WH)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Gender differences in gathering with NHM
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Age differences in gathering with NHM during Thanksgiving
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Age differences in gathering with NHM during winter holidays
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Ethnic differences in gathering with NHM
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Mask wearing during Thanksgiving gatherings
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Mask wearing during winter holiday gatherings
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Mask wearing differences among demographics during gatherings with NHM
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Overall adherence to public health safety behaviors
Number of subjects: 20000
Study: 34383274

Group type: EXPERIMENTAL
Intervention: Transcutaneous trigeminal electrical neuromodulation (TTEN)
Number of subjects: 13
Study: 34383289

Group type: EXPERIMENTAL
Intervention: Intravenous onasemnogene abeparvovec
Number of subjects: 102
Study: 34383370

Group type: EXPERIMENTAL
Intervention: Sorafenib (150 mg/m² continuous oral twice daily) with Irinotecan (oral, once daily days 1-5, every 21 days)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sorafenib (150 mg/m²)
Number of subjects: 15
Study: 34383393

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy
Number of subjects: 0
Study: 34383569

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34383662

Group type: EXPERIMENTAL
Intervention: VR simultaneous motor-cognitive training (cognitive games and cycling on an ergometer simultaneously on a VR platform)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (cognitive games on tablet computers and cycling on the ergometer sequentially on a non-VR platform)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: VR simultaneous motor-cognitive training
Number of subjects: 17
Study: 34383675

Group type: EXPERIMENTAL
Intervention: Shared review process of electronic patient-reported outcomes (ePRO)
Number of subjects: 181
Study: 34383676

Group type: EXPERIMENTAL
Intervention: Bizi Orain, a 3-month supervised exercise program (3 times a week) with behavioral counseling in a primary health care setting.
Number of subjects: 265

Group type: COMPARATOR
Intervention: Delayed treatment (control group).
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Overall survival (prospective study).
Number of subjects: 265
Study: 34383681

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) treatment
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 133